Bio-Rad Laboratories (BIO) 10-Q 30 Apr 21 2021 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2021	Apr. 23, 2021
Document Transition Report	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Shell Company	false
City Area Code	(510)
Document Quarterly Report	true
Entity Incorporation, State or Country Code	DE
Entity File Number	1-7928
Entity Registrant Name	BIO-RAD LABORATORIES, INC.
Entity Central Index Key	0000012208
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Small Business	false
Entity Tax Identification Number	94-1381833
Entity Address, Address Line One	1000 Alfred Nobel Drive,
Entity Address, City or Town	Hercules,
Entity Address, Country	CA
Entity Address, Postal Zip Code	94547
Local Phone Number	724-7000
Entity Emerging Growth Company	false
Common Class A [Member]
Title of 12(b) Security	Class A Common Stock, Par Value $0.0001 per share
Trading Symbol	BIO
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		24,692,554
Common Class B [Member]
Title of 12(b) Security	Class B Common Stock, Par Value $0.0001 per share
Trading Symbol	BIOb
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		5,071,060

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
ASSETS:
Cash and cash equivalents	$ 673,470,000	$ 662,205,000
Short-term investments	346,398,000	328,913,000
Restricted investments	5,560,000	5,560,000
Accounts receivable, net	408,137,000	419,424,000
Inventories:
Raw materials	122,605,000	126,911,000
Work in process	150,628,000	151,931,000
Finished goods	331,923,000	343,411,000
Total inventories	605,156,000	622,253,000
Prepaid expenses	110,271,000	90,621,000
Other current assets	26,325,000	10,859,000
Total current assets	2,175,317,000	2,139,835,000
Property, plant, and equipment	1,420,284,000	1,452,761,000
Less: accumulated depreciation and amortization	937,572,000	961,390,000
Property, plant and equipment, net	482,712,000	491,371,000
Operating lease right-of-use assets	196,224,000	202,136,000
Goodwill, net	291,916,000	291,916,000
Purchased intangibles, net	191,764,000	199,497,000
Other investments	10,503,038,000	9,561,140,000
Other assets	92,189,000	86,723,000
Assets	13,933,160,000	12,972,618,000
LIABILITIES AND STOCKHOLDERS' EQUITY:
Accounts payable	138,494,000	139,451,000
Accrued payroll and employee benefits	174,889,000	222,875,000
Current maturities of long-term debt and notes payable	1,738,000	1,798,000
Income and other taxes payable	89,074,000	57,335,000
Current operating lease liabilities	39,235,000	36,507,000
Other current liabilities	166,462,000	173,570,000
Total current liabilities	609,892,000	631,536,000
Long-term debt, net of current maturities	10,901,000	12,258,000
Deferred income taxes	2,306,112,000	2,076,785,000
Operating lease liabilities	168,326,000	175,128,000
Other long-term liabilities	228,870,000	196,971,000
Total liabilities	3,324,101,000	3,092,678,000
Stockholders' equity:
Additional paid-in capital	445,101,000	429,376,000
Retained earnings	10,245,426,000	9,268,012,000
Accumulated other comprehensive loss	68,434,000	282,456,000
Total stockholders' equity	10,609,059,000	9,879,940,000
Total liabilities and stockholders' equity	13,933,160,000	12,972,618,000
Accounts receivable allowance for doubtful accounts	18,553,000	19,807,000
Common Class A [Member]
Stockholders' equity:
Common stock	$ 2,000	$ 2,000
Common Stock, Shares, Issued	25,086,359	25,072,619
Common Stock, Shares, Outstanding	24,692,104	24,767,870
Common Class B [Member]
Stockholders' equity:
Common stock	$ 1,000	$ 1,000
Common Stock, Shares, Issued	5,071,060	5,076,186
Common Stock, Shares, Outstanding	5,071,060	5,076,186
Treasury Class A [Member]
Stockholders' equity:
Treasury stock	$ (149,905,000)	$ (99,907,000)
Treasury Stock, Shares	394,255	304,749

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets Parenthetical - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Accounts receivable allowance for doubtful accounts	$ 18,553	$ 19,807
Common Class A [Member]
Common Stock, Shares, Issued	25,086,359	25,072,619
Common Stock, Shares, Outstanding	24,692,104	24,767,870
Common Class B [Member]
Common Stock, Shares, Issued	5,071,060	5,076,186
Common Stock, Shares, Outstanding	5,071,060	5,076,186
Treasury Class A [Member]
Treasury Stock, Shares	394,255	304,749

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net sales	$ 726,796	$ 571,644
Cost of goods sold	326,169	254,276
Gross profit	400,627	317,368
Selling, general and administrative expense	225,853	193,692
Research and Development Expense	73,912	49,303
Segment profit (loss)	100,862	74,373
Interest expense	398	5,690
Foreign exchange (gains) losses, net	71	928
Marketable Securities, Unrealized (Gain) Loss	(1,179,403)	(827,671)
Other Nonoperating Income (Expense)	17,407	3,273
Income before income taxes	1,297,203	898,699
(Provision) benefit for income taxes	(319,789)	(212,787)
Net income attributable to Bio-Rad	$ 977,414	$ 685,912
Basic earnings per share:
Net income per share basic attributable to Bio-Rad	$ 32.77	$ 22.97
Weighted average common shares - basic	29,823	29,865
Diluted earnings per share:
Net income per share diluted attributable to Bio-Rad	$ 32.38	$ 22.72
Weighted average common shares - diluted	30,186	30,196

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net Income (Loss) Attributable to Parent	$ 977,414	$ 685,912
Foreign currency translation adjustments	(214,323)	(62,011)
Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax, Portion Attributable to Parent	1,857	731
Net unrealized holding gains (losses) on available-for-sale investments net of tax expense	(1,556)	(327)
Total other comprehensive income (loss) net of tax	(214,022)	(61,607)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	$ 763,392	$ 624,305

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Cash received from customers	$ 728,013	$ 569,001
Cash paid to suppliers and employees	(612,803)	(509,683)
Interest paid, net	(309)	(231)
Income tax payments, net	(14,727)	(4,528)
Investment proceeds and miscellaneous receipts, net	12,193	3,912
Proceeds from forward foreign exchange contracts, net	1,243	4,337
Net cash provided by operating activities	113,610	62,808
Cash flows from investing activities:
Capital expenditures	(19,547)	(21,591)
Proceeds from dispositions of property, plant and equipment	12	38
Payments for purchases of marketable securities and investments	(74,925)	(98,151)
Proceeds from maturities of marketable securities and investments	30,509	67,710
Proceeds from Sale of Debt Securities, Available-for-sale	15,624	39,672
(Payments for) recovery of purchases of intangible assets	0	(100)
Net cash used in investing activities	(48,327)	(12,422)
Cash flows from financing activities:
Payments on long-term borrowings	(1,401)	(1,415)
Payments of contingent consideration	0	(1,265)
Proceeds from Issuance of Common Stock	4,052	4,068
Payments for purchases of treasury stock	(49,998)	(100,005)
Net cash used in financing activities	(47,347)	(98,617)
Effect of Exchange Rate on Cash and Cash Equivalents	(7,347)	(5,977)
Beginning Cash, Cash Equivalents, and Restricted Cash	667,115	662,651
Cash and cash equivalents	673,470	603,551
Ending Cash, Cash Equivalents, and Restricted Cash	677,704	608,443
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect	10,589	(54,208)
Other Current Assets
Cash flows from financing activities:
Restricted Cash, Current	3,354	3,110
Other Assets
Cash flows from financing activities:
Restricted Cash, Noncurrent	$ 880	$ 1,782

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity Statement - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]
Total Stockholders' Equity at Dec. 31, 2019	$ 5,755,057	$ 3	$ 410,020	$ (38,397)	$ 5,470,779	$ (87,348)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	685,912	0	0	0	685,912	0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(61,607)	0	0	0	0	(61,607)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	9,654	0	9,654	0	0	0
Proceeds from Issuance of Common Stock	4,068	0	4,068	0	0	0
Treasury Stock, Value, Acquired, Cost Method	(100,005)	0	0	(100,005)	0	0
Total Stockholders' Equity at Mar. 31, 2020	6,293,079	3	423,742	(138,402)	6,156,691	(148,955)
Total Stockholders' Equity at Dec. 31, 2020	9,879,940	3	429,376	(99,907)	9,268,012	282,456
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net Income (Loss) Attributable to Parent	977,414	0	0	0	977,414	0
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent	(214,022)	0	0	0	0	(214,022)
APIC, Share-based Payment Arrangement, Increase for Cost Recognition	11,673	0	11,673	0	0	0
Proceeds from Issuance of Common Stock	4,052	0	4,052	0	0	0
Treasury Stock, Value, Acquired, Cost Method	(49,998)	0	0	(49,998)	0	0
Total Stockholders' Equity at Mar. 31, 2021	$ 10,609,059	$ 3	$ 445,101	$ (149,905)	$ 10,245,426	$ 68,434

1. Basis of Presentation and Us

1. Basis of Presentation and Use of Estimates	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure	BASIS OF PRESENTATION AND USE OF ESTIMATES Basis of Presentation In this report, “Bio-Rad,” “we,” “us,” “the Company” and “our” refer to Bio-Rad Laboratories, Inc. and its subsidiaries. The accompanying unaudited condensed consolidated financial statements of Bio-Rad have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) and reflect all adjustments which are, in the opinion of management, necessary to fairly state the results of the interim periods presented. All such adjustments are of a normal recurring nature. Results for the interim period are not necessarily indicative of the results for the entire year. The condensed consolidated balance sheet at December 31, 2020 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. The condensed consolidated financial statements should be read in conjunction with the notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2020. We evaluate subsequent events and the evidence they provide about conditions existing at the date of the balance sheet as well as conditions that arose after the balance sheet date but through the date the financial statements are issued. The effects of conditions that existed at the balance sheet date are recognized in the financial statements. Events and conditions arising after the balance sheet date but before the financial statements are issued are evaluated to determine if disclosure is required to keep the financial statements from being misleading. To the extent such events and conditions exist, disclosures are made regarding the nature of events and the estimated financial effects of those events and conditions. Use of Estimates The preparation of the condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingencies at the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting periods. Bio-Rad bases its estimates on historical experience and on various other market-specific and other relevant assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates. Revenue Recognition We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recognized until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to customer specifications, which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control in relation to the equipment has occurred at that point as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon customer acceptance because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. At the time revenue is recognized, a provision is recorded for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance. We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. Reagent Rental Agreements Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. For purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the Company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Generally these arrangements do not contain an option for the lessee to purchase the underlying asset. We concluded that the use of the instrument (referred to as “lease elements”) is not within the guidance of ASC 606 but rather ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After allocation, the amount of variable payments allocated to lease components will be recognized as income under ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Maintenance services, along with the reagents, are allocated to the non-lease elements and are recognized as income. Generally, the terms of the arrangements result in the transfer of control for reagents upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer. Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as very few of such arrangements contain any fixed/minimum lease payments. Further, our reagent rental arrangements are predominantly classified as operating leases, and any sales-type leases represent in aggregate an immaterial amount of lease income. Our reported lease income is primarily variable in nature and is recognized upon delivery or as the reagents are consumed by the customer. Revenue allocated to the lease elements of these reagent rental arrangements represented approximately 2% and 3% of total revenue for the three months ended March 31, 2021 and March 31, 2020, respectively, and are included as part of Net sales in our condensed consolidated statements of income. Contract costs: As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income. Disaggregation of Revenue: The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions): Three Months Ended March 31, 2021 2020 Europe $ 247.7 $ 195.7 Asia 168.9 111.4 United States 271.4 229.5 Other (primarily Canada and Latin America) 38.8 35.0 Total net sales $ 726.8 $ 571.6 The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenue by industry segment sources are presented in our Segment Information footnote (see Note 10). Deferred revenues primarily represents unrecognized fees billed or collected for extended service arrangements. The deferred revenue balance at March 31, 2021 and December 31, 2020 was $66.2 million and $60.0 million, respectively. The short-term deferred revenue balance at March 31, 2021 and December 31, 2020 was $48.0 million and $42.5 million, respectively. We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income. Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the three month period ended March 31, 2021 and 2020 were as follows (in millions): Three Months Ended March 31, 2021 2020 Balance at beginning of period $ 9.8 $ 9.0 Provision for warranty 2.7 1.9 Actual warranty costs (2.6) (2.7) Balance at end of period $ 9.9 $ 8.2 Allowance for Doubtful Accounts We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. We review our exposure to accounts receivable and reserve for amounts if collectability is no longer reasonably assured based on an assessment of various factors including historical loss rates and expectations of forward-looking loss estimates. Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer. Changes in our allowance for doubtful accounts were as follows (in millions): Three Months Ended March 31, 2021 2020 Balance at beginning of period $ 19.8 $ 20.2 Provision (recovery) for expected credit losses (0.6) (0.8) Write-offs charged against the allowance (0.6) (0.5) Balance at end of period $ 18.6 $ 18.9 Recent Accounting Pronouncements Adopted In March 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-04, "Facilitation of the Effects of Reference Rate Reform on Financial Reporting (Topic 848)" The ASU provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate (e.g., LIBOR) reform if certain criteria are met, for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The ASU is effective as of March 12, 2020 through December 31, 2022. We will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. The ASU is currently not expected to have a material impact on our condensed consolidated financial statements. In January 2020, the FASB issued ASU 2020-01, "Clarifying the Interactions between Topic 321 Investments—Equity Securities, Topic 323 Investments—Equity Method and Joint Ventures, and Topic 815 Derivatives and Hedging." ASU 2020-01 clarifies that a company should consider observable transactions that require a company to either apply or discontinue the equity method of accounting under Topic 323 for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. ASU 2020-01 also clarifies that, when determining the accounting for certain forward contracts and purchased options a company should not consider, whether upon settlement or exercise, if the underlying securities would be accounted for under the equity method or fair value option. The ASU is currently not expected to have a material impact on our condensed consolidated financial statements. In December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes," which eliminates certain exceptions within ASC 740, Income Taxes, and clarifies other aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 was effective for fiscal years beginning after December 15, 2020, with any adjustments reflected as of January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the condensed consolidated financial statements.

2. Fair Value Measurements

2. Fair Value Measurements	3 Months Ended
	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS We determine the fair value of an asset or liability based on the assumptions that market participants would use in pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritizes the inputs into three broad levels as follows: • Level 1: Quoted prices in active markets for identical instruments • Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments) • Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments) Financial assets and liabilities carried at fair value and measured on a recurring basis as of March 31, 2021 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 29.3 $ — $ 29.3 U.S. government sponsored agencies — 2.6 — 2.6 Time deposits 8.7 10.0 — 18.7 Money market funds 61.3 — — 61.3 Total cash equivalents (a) 70.0 41.9 — 111.9 Restricted investments (b) 6.8 — — 6.8 Equity securities (c) 10,524.3 — — 10,524.3 Available-for-sale investments: Corporate debt securities — 162.2 — 162.2 U.S. government sponsored agencies — 71.8 — 71.8 Foreign government obligations — 4.0 — 4.0 Other foreign obligations — 2.1 — 2.1 Municipal obligations — 14.1 — 14.1 Asset-backed securities — 28.1 — 28.1 Total available-for-sale investments (d) — 282.3 — 282.3 Forward foreign exchange contracts (e) — 0.6 — 0.6 Total financial assets carried at fair value $ 10,601.1 $ 324.8 $ — $ 10,925.9 Financial liabilities carried at fair value: Forward foreign exchange contracts (f) $ — $ 1.1 $ — $ 1.1 Contingent consideration (g) — — 0.7 0.7 Total financial liabilities carried at fair value $ — $ 1.1 $ 0.7 $ 1.8 Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2020 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 41.7 $ — $ 41.7 Time deposits 17.6 10.0 — 27.6 Asset-backed securities — 0.9 — 0.9 U.S. government sponsored agencies — 2.5 — 2.5 Money market funds 60.1 — — 60.1 Total cash equivalents (a) 77.7 55.1 — 132.8 Restricted investments (b) 6.7 — — 6.7 Equity securities (c) 9,582.4 — — 9,582.4 Available-for-sale investments: Corporate debt securities — 133.2 — 133.2 U.S. government sponsored agencies — 76.9 — 76.9 Foreign government obligations — 4.0 — 4.0 Other foreign obligations — 2.1 — 2.1 Municipal obligations — 15.2 — 15.2 Asset-backed securities — 36.2 — 36.2 Total available-for-sale investments (d) — 267.6 — 267.6 Forward foreign exchange contracts (e) — 1.0 — 1.0 Total financial assets carried at fair value $ 9,666.8 $ 323.7 $ — $ 9,990.5 Financial liabilities carried at fair value: Forward foreign exchange contracts (f) $ — $ 1.0 $ — $ 1.0 Contingent consideration (g) — — 0.7 0.7 Total financial liabilities carried at fair value $ — $ 1.0 $ 0.7 $ 1.7 (a) Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets. (b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions): March 31, 2021 December 31, 2020 Restricted investments $ 5.6 $ 5.6 Other investments 1.2 1.1 Total $ 6.8 $ 6.7 (c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions): March 31, 2021 December 31, 2020 Short-term investments $ 64.2 $ 61.4 Other investments 10,460.1 9,521.0 Total $ 10,524.3 $ 9,582.4 The change in fair market value on our equity securities for the three months ended March 31, 2021 was a $1,179.4 million gain, which was primarily due to our investment in Sartorius AG and is recorded in our condensed consolidated statements of income. As of March 31, 2021, we own 12,987,900 ordinary voting shares and 9,588,908 preferenc e shares of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own approximately 37% of the ordinary outstanding voting shares (excluding treasury shares) and 28% of the preference shares of Sartorius as of March 31, 2021. (d) Available-for-sale investments are included in the following accounts in the condensed consolidated balance sheets (in millions): March 31, 2021 December 31, 2020 Short-term investments $ 282.2 $ 267.5 Other investments 0.1 0.1 Total $ 282.3 $ 267.6 (e) Forward foreign exchange contracts in an asset position are included in other current assets in the condensed consolidated balance sheets. (f) Forward foreign exchange contracts in a liability position are included in other current liabilities in the condensed consolidated balance sheets. (g) Contingent consideration liability is included in the following accounts in the condensed consolidated balance sheets (in millions): March 31, 2021 December 31, 2020 Other current liabilities $ 0.6 $ 0.6 Other long-term liabilities 0.1 0.1 Total $ 0.7 $ 0.7 During the fourth quarter of 2019, we recognized a contingent consideration liability for earn-out targets related to our acquisition of a foreign distributor. The first earn-out payment of $0.7 million was paid by the acquisition date and the remaining payment is anticipated to be paid in the first half of 2021. The maximum earn-out payment due is $1.4 million. The contingent consideration was accrued at its estimated fair value of $0.6 million as of March 31, 2021 which is unchanged from the fair value at December 31, 2020. During the second quarter of 2020, we recognized a contingent consideration liability upon our acquisition of Celsee, Inc. which represents the future potential earn-out payments of up to $60.0 million payable in cash upon the achievement of certain net revenues for the period beginning on January 1, 2021 and ending on December 31, 2022. The fair value of the earn-out as of the Acquisition Date was approximately $0.1 million which was determined by using a Black-Scholes-Merton option-pricing valuation model that includes significant assumptions and unobservable inputs such as the projected revenues of Celsee over the earn-out period and the probability of the earn-out threshold being met. The fair value of the contingent consideration is remeasured at each reporting period based on the assumptions and inputs on the date of remeasurement. The achievement of net revenues was not met as of March 31, 2021 and therefore the fair value of the earn-out remained unchanged at approximately $0.1 million as of March 31, 2021. To estimate the fair value of Level 2 debt securities as of March 31, 2021, our primary pricing provider uses Reuters as the primary pricing source. Our pricing process allows us to select a hierarchy of pricing sources for securities held. If Reuters does not price a Level 2 security that we hold, then the pricing provider will utilize our custodian supplied pricing as the secondary pricing source. Available-for-sale investments consist of the following (in millions): March 31, 2021 Amortized Unrealized Unrealized Allowances for Credit Losses Fair Short-term investments: Corporate debt securities $ 160.3 $ 1.9 $ — $ — $ 162.2 Municipal obligations 14.0 0.1 — — 14.1 Asset-backed securities 27.7 0.3 — — 28.0 U.S. government sponsored agencies 70.6 1.3 (0.1) — 71.8 Foreign government obligations 4.0 — — — 4.0 Other foreign obligations 2.1 — — — 2.1 278.7 3.6 (0.1) — 282.2 Long-term investments: Asset-backed securities 0.1 — — — 0.1 0.1 — — — 0.1 Total $ 278.8 $ 3.6 $ (0.1) $ — $ 282.3 The following is a summary of the amortized cost and estimated fair value of our debt securities at March 31, 2021 by contractual maturity date (in millions): Amortized Estimated Fair Mature in less than one year $ 173.6 $ 174.1 Mature in one to five years 66.2 67.9 Mature in more than five years 39.0 40.3 Total $ 278.8 $ 282.3 Available-for-sale investments consist of the following (in millions): December 31, 2020 Amortized Unrealized Unrealized Allowances for Credit Losses Estimated Short-term investments: Corporate debt securities $ 130.5 $ 2.7 $ — — $ 133.2 Municipal obligations 15.0 0.2 — — 15.2 Asset-backed securities 35.8 0.3 — — 36.1 U.S. government sponsored agencies 74.7 2.2 — — 76.9 Foreign government obligations 4.0 — — — 4.0 Other foreign obligations 2.1 — — — 2.1 262.1 5.4 — — 267.5 Long-term investments: Asset-backed securities 0.1 — — — 0.1 0.1 — — — 0.1 Total $ 262.2 $ 5.4 $ — $ — $ 267.6 The following is a summary of investments with gross unrealized losses and the associated fair value (in millions): March 31, 2021 Less than 12 months Greater than 12 months Total Description of securities: Fair Value Unrealized Losses Fair Value Unrealized Losses Fair Value Unrealized Losses U.S. government sponsored agencies 7.4 0.1 — — 7.4 0.1 Total $ 7.4 $ 0.1 $ — $ — $ 7.4 $ 0.1 The unrealized losses of $0.1 million as of March 31, 2021 are due to a number of factors, including changes in interest rates, changes in economic conditions and changes in market outlook for various industries, among others. There were no significant unrealized losses as of December 31, 2020 in either the less than or greater than 12 month categories. Our evaluation of credit losses for available-for-sale debt securities included t he extent to which the fair value is less than the amortized cost basis, adverse conditions specifically related to the debt security, an industry or geographic area, and any changes in the rating of a security by a rating agency. Credit loss impairments are limited to the amount that the fair value of an instrument is less than its amortized cost basis. At March 31, 2021, we have concluded that all payments related to our available-for-sale investments are expected to be made in full and on time at par value. The diminution of value in the intervening period is due to market conditions such as illiquidity and interest rate movements and not due to significant, inherent credit concerns surrounding the issuer. As a result, we have no allowances for credit losses on our available-for-sale investments portfolio as of March 31, 2021. Included in other current assets are $1.4 million of interest receivable as of March 31, 2021 and December 31, 2020, primarily associated with securities in our available-for-sale investments portfolio. Associated interest on these securities is typically payable semi-annually. Due to the short-term nature of our interest receivable asset, we have made an accounting policy election not to measure an allowance for credit losses for accrued interest receivable. We consider any uncollected interest receivable that is overdue greater than one year to be impaired for purposes of write-off. For the three months ended March 31, 2021, we have not written-off any uncollected interest receivable. As part of distributing our products, we regularly enter into intercompany transactions. We enter into forward foreign exchange contracts to manage foreign exchange risk of future movements in foreign exchange rates that affect foreign currency denominated intercompany receivables and payables. We do not use derivative financial instruments for speculative or trading purposes. We do not seek hedge accounting treatment for these contracts. As a result, these contracts, generally with maturity dates of 90 days or less and denominated primarily in currencies of industrial countries, are recorded at their fair value at each balance sheet date. The notional principal amounts provide one measure of the transaction volume outstanding as of March 31, 2021 and do not represent the amount of Bio-Rad's exposure to loss. The estimated fair value of these contracts was derived using the spot rates from Reuters on the last business day of the quarter and the points provided by counterparties. The resulting gains or losses offset exchange gains or losses on the related receivables and payables, both of which are included in foreign currency exchange losses, net in the condensed consolidated statements of income. The following is a summary of our forward foreign exchange contracts (in millions): March 31, 2021 Contracts maturing in April through June 2021 to sell foreign currency: Notional value $ 284.0 Unrealized loss $ 0.4 Contracts maturing in April through June 2021 to purchase foreign currency: Notional value $ 252.3 Unrealized gain or loss $ — Included in other investments in the condensed consolidated balance sheets are investments without readily determinable fair value measured at cost with adjustments for observable price changes in price or impairments. The carrying value of these investments was $6.5 million and $0.5 million as of March 31, 2021 and December 31, 2020, respectively. Also included in other investments in the condensed consolidated balance sheets are our equity method investments, for which our share of the equity method investees earnings is included in other income, net in our condensed consolidated statements of income. The carrying value of these investments was $35.2 million and $38.4 million as of March 31, 2021 and December 31, 2020, respectively.

3. Intangible Assets, Goodwill

3. Intangible Assets, Goodwill and Other	3 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure	GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS Changes to goodwill by segment were as follows (in millions): Life Clinical Total Balances as of March 31, 2021 and December 31, 2020: Goodwill 277.9 349.2 627.1 Accumulated impairment losses (41.8) (293.4) (335.2) Goodwill, net $ 236.1 $ 55.8 $ 291.9 Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions): March 31, 2021 Weighted-Average Remaining Amortization Period (years) Purchase Accumulated Net Customer relationships/lists 5.47 $ 112.4 $ (85.6) $ 26.8 Know how 4.50 192.7 (172.6) 20.1 Developed product technology 13.83 217.1 (108.6) 108.5 Licenses 7.51 65.2 (38.0) 27.2 Tradenames 7.71 6.4 (4.2) 2.2 Covenants not to compete 3.66 4.6 (2.2) 2.4 Other — 0.1 (0.1) — Total definite-lived intangible assets 598.5 (411.3) 187.2 In-process research and development 4.6 — 4.6 Total purchased intangible assets $ 603.1 $ (411.3) $ 191.8 December 31, 2020 Weighted-Average Remaining Amortization Period (years) Purchase Accumulated Net Customer relationships/lists 5.51 $ 116.6 $ (87.2) $ 29.4 Know how 4.75 196.6 (175.4) 21.2 Developed product technology 14.00 218.1 (107.1) 111.0 Licenses 7.73 65.6 (37.4) 28.2 Tradenames 7.82 6.6 (4.2) 2.4 Covenants not to compete 3.87 4.5 (2.0) 2.5 Other — 0.1 (0.1) — Total definite-lived intangible assets 608.1 (413.4) 194.7 In-process research and development 4.8 — 4.8 Total purchased intangible assets $ 612.9 $ (413.4) $ 199.5 Amortization expense related to purchased intangible assets is as follows (in millions): Three Months Ended March 31, 2021 2020 Amortization expense $ 7.2 $ 5.9

4. Statement of Cash Flows, Sup

4. Statement of Cash Flows, Supplemental Disclosures	3 Months Ended
	Mar. 31, 2021
Supplemental Cash Flow Elements [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	SUPPLEMENTAL CASH FLOW INFORMATION The reconciliation of net income to net cash provided by operating activities is as follows (in millions): Three Months Ended March 31, 2021 March 31, 2020 Net income $ 977.4 $ 685.9 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 32.7 33.6 Reduction in the carrying amount of right-of-use assets 9.8 9.6 Share-based compensation 11.7 9.7 Gains on dispositions of securities (0.1) (0.4) Other-than-temporary impairment losses on investment 0.8 — Changes in fair market value of equity securities (1,179.4) (827.7) Losses on dispositions of fixed assets 0.3 0.1 Changes in fair value of contingent consideration — (0.1) Payments for operating lease liabilities (9.9) (9.3) Decrease in accounts receivable 1.3 2.2 Decrease (increase) in inventories 5.8 (13.7) Increase in other current assets (37.5) (9.5) Decrease in accounts payable and other current liabilities (44.5) (25.6) Increase in income taxes payable 27.3 20.9 Increase in deferred income taxes 274.8 171.8 Increase in other long term liabilities 43.8 15.7 Other (0.7) (0.4) Net cash provided by operating activities $ 113.6 $ 62.8 Non-cash investing activities: Purchased property, plant and equipment $ 4.7 $ 6.0 Purchased marketable securities and investments $ — $ 2.7

5. Long-Term Debt

5. Long-Term Debt	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Long-term Debt	5. LONG-TERM DEBT The principal components of long-term debt are as follows (in millions): March 31, December 31, Finance leases and other debt $ 12.6 $ 14.1 Less current maturities (1.7) (1.8) Long-term debt $ 10.9 $ 12.3 Credit Agreement In April 2019, Bio-Rad entered into a $200.0 million unsecured revolving credit facility ("Credit Agreement"). Borrowings under the Credit Agreement are on a revolving basis and can be used to make permitted acquisitions, for working capital and for other general corporate purposes. We had no outstanding borrowings under the Credit Agreement as of March 31, 2021; however, $0.2 million was utilized for domestic standby letters of credit that reduced our borrowing availability as of March 31, 2021. The Credit Agreement matures in April 2024. If we had borrowed against our Credit Agreement, the borrowing rate would have been 1.315% at March 31, 2021, which is based on the 3-month LIBOR. The Credit Agreement requires Bio-Rad to comply with certain financial ratios and covenants, among other things. These ratios and covenants include a leverage ratio test and an interest coverage test, as well as restrictions on our ability to declare or pay dividends, incur debt, guarantee debt, enter into transactions with affiliates, merge or consolidate, sell assets, make investments and create liens. We were in compliance with all of these ratios and covenants as of March 31, 2021.

6. Accumulated Other Comprehens

6. Accumulated Other Comprehensive Income 7. Accumulated Other Comprehensive Income (Notes)	3 Months Ended
	Mar. 31, 2021
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	6. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Accumulated other comprehensive income included in our condensed consolidated balance sheets consists of the following components (in millions): Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains on available-for-sale investments Total accumulated other comprehensive income (loss) Balances as of January 1, 2021: $ 298.6 $ (26.0) $ 9.8 $ 282.4 Other comprehensive (loss) income, before reclassifications (214.7) 1.7 (1.9) (214.9) Amounts reclassified from Accumulated other comprehensive income — 0.5 (0.1) 0.4 Income tax effects 0.4 (0.3) 0.4 0.5 Other comprehensive (loss) income, net of income taxes (214.3) 1.9 (1.6) (214.0) Balances as of March 31, 2021: $ 84.3 $ (24.1) $ 8.2 $ 68.4 Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains on available-for-sale investments Total accumulated other comprehensive income (loss) Balances as of January 1, 2020: $ (72.4) $ (22.2) $ 7.2 $ (87.4) Other comprehensive (loss) income, before reclassifications (62.9) 0.2 — (62.7) Amounts reclassified from Accumulated other comprehensive income — 0.3 (0.4) (0.1) Income tax effects 0.9 0.2 0.1 1.2 Other comprehensive (loss) income, net of income taxes (62.0) 0.7 (0.3) (61.6) Balances as of March 31, 2020: $ (134.4) $ (21.5) $ 6.9 $ (149.0) All amounts reclassified out of accumulated other comprehensive income were reclassified into other income, net in the condensed consolidated statements of income. The reclassification adjustments are calculated using the specific identification method.

7. Earnings Per Share

7. Earnings Per Share	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Earnings Per Share	. EARNINGS PER SHARE Basic earnings per share is computed by dividing net income attributable to Bio-Rad by the weighted average number of common shares outstanding for that period. Diluted earnings per share takes into account the effect of dilutive instruments, such as stock options and restricted stock, and uses the average share price for the period in determining the number of potential common shares that are to be added to the weighted average number of shares outstanding. Potential common shares are excluded from the diluted earnings per share calculation if the effect of including such securities would be anti-dilutive. The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands): Three Months Ended March 31, 2021 2020 Basic weighted average shares outstanding 29,823 29,865 Effect of potentially dilutive stock options and restricted stock awards 363 331 Diluted weighted average common shares 30,186 30,196 Anti-dilutive shares 23 62

8. Other Income and Expenses

8. Other Income and Expenses	3 Months Ended
	Mar. 31, 2021
Other Income and Expenses [Abstract]
Other Income and Other Expense Disclosure	. OTHER INCOME AND EXPENSE, NET Other (income) expense, net includes the following components (in millions): Three Months Ended March 31, 2021 2020 Interest and investment income $ (18.3) $ (2.8) Net realized gains on investments (0.1) (0.4) Other-than-temporary impairment loss on investment 0.8 — Other expense (income) 0.2 (0.1) Other (income), net $ (17.4) $ (3.3)

9. Income Taxes

9. Income Taxes	3 Months Ended
	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	9. INCOME TAXES Our effective income tax rate was 24.7% and 23.7% for the three months ended March 31, 2021 and 2020, respectively. The realization of deferred tax assets is dependent upon the generation of sufficient taxable income of the appropriate character in future periods. We regularly assess our ability to realize our deferred tax assets and establish a valuation allowance if it is more likely than not that some portion, or all, of our deferred tax assets will not be realized. In assessing the realizability of our deferred tax assets, we weigh all available positive and negative evidence. Due to the weight of objectively verifiable negative evidence, we believe that it is more likely than not that certain foreign deferred tax assets will not be realized as of March 31, 2021, and have maintained a valuation allowance on such deferred tax assets. Our income tax returns are routinely audited by U.S. federal, state and foreign tax authorities. We are currently under examination by many of these tax authorities. There are differing interpretations of tax laws and regulations, and as a result, significant disputes may arise with these tax authorities involving issues around the timing and amount of deductions and allocations of income among various tax jurisdictions. We evaluate our exposures associated with our tax filing positions on a quarterly basis. We record liabilities for unrecognized tax benefits related to uncertain tax positions. We do not believe any currently pending uncertain tax positions will have a material adverse effect on our condensed consolidated financial statements, although an adverse resolution of one or more of these uncertain tax positions in any period may have a material impact on the results of operations for that period. Our gross unrecognized tax benefits were $57.5 million and $55.8 million as of March 31, 2021 and December 31, 2020, respectively. The increase to our gross unrecognized tax benefits is primarily the result of a $1.7 million net increase in tax positions taken in the current year net of foreign currency translation adjustments. As of March 31, 2021, based on the expected outcome of certain examinations or as a result of the expiration of statutes of limitations for certain jurisdictions, we believe that within the next 12 months it is reasonably possible that our previously unrecognized tax benefits could decrease by up to $16.7 million primarily related to various foreign jurisdictions.

10. Segment Information Segment

10. Segment Information Segment Reporting	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Segment Reporting Disclosure [Text Block]	SEGMENT INFORMATION Information regarding operating segments for the three months ended March 31, 2021 and 2020 is as follows (in millions): Life Clinical Other Segment net sales 2021 $ 366.5 $ 358.5 $ 1.8 2020 $ 227.2 $ 340.3 $ 4.1 Segment net profit (loss) 2021 $ 102.3 $ (1.9) $ 0.1 2020 $ 23.7 $ 43.8 $ 1.1 Segment results are presented in the same manner as we present our operations internally to make operating decisions and assess performance. Our chief operating decision maker ("CODM") views all operating expenses, interest expense and corporate overhead as directly supporting the strategies of our segments. As a result, starting in 2021 these costs are fully allocated to our reportable segments. Prior to this change, the difference between total segment allocated interest expense, depreciation and amortization, and the corresponding consolidated amounts was attributable to our corporate headquarters. The historical segment information has been recast to conform to the current allocation methodology of corporate operating and other expenses to the segments. Interest expense is charged to segments based on the carrying amount of inventory and receivables employed by that segment. The following reconciles total segment profit to consolidated income before income taxes (in millions): Three Months Ended March 31, 2021 2020 Total segment profit $ 100.5 $ 68.6 Foreign currency exchange losses, net (0.1) (0.9) Change in fair market value of equity securities 1,179.4 827.7 Other income, net 17.4 3.3 Consolidated income before income taxes $ 1,297.2 $ 898.7

11. Legal Proceedings

11. Legal Proceedings	3 Months Ended
	Mar. 31, 2021
Loss Contingency, Information about Litigation Matters [Abstract]
Legal Proceedings.	11. LEGAL PROCEEDINGS We are a party to various claims, legal actions and complaints arising in the ordinary course of business. We cannot at this time reasonably estimate a range of exposure, if any, of the potential liability with respect to these matters. While we do not believe, at this time, that any ultimate liability resulting from any of these other matters will have a material adverse effect on our results of operations, financial position or liquidity, we cannot give any assurance regarding the ultimate outcome of these other matters and their resolution could be material to our operating results for any particular period, depending on the level of income for the period.

12. Restructuring Costs (Notes)

12. Restructuring Costs (Notes)	3 Months Ended
	Mar. 31, 2021
Restructuring Costs [Abstract]
Restructuring and Related Activities Disclosure [Text Block]	RESTRUCTURING COSTSIn February 2021, we announced our strategy-driven restructuring plan in furtherance of our ongoing program to improve operating performance. The restructuring plan primarily impacts our operations in Europe and includes the elimination of certain positions, the consolidation of certain functions, and the relocation of certain manufacturing operations from Europe to Asia. The restructuring plan will be implemented in phases and is expected to be substantially complete by the end of 2022. The liability of $71.2 million as of March 31, 2021 consisted of $35.2 million recorded in Accrued payroll and employee benefits and $36.0 million recorded in Other long-term liabilities in the condensed consolidated balance sheets. The amounts reflected in Cost of goods sold, Selling, general and administrative expense and Research and development expense were $23.9 million, $34.7 million and $17.0 million in the condensed consolidated statements of income for the three months ended March 31, 2021, respectively. The amounts are preliminary estimates based on the information currently available to management. It is possible that additional adjustments and future cash payments could occur in relation to the restructuring actions. The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions): Life Science Clinical Diagnostics Total Balances as of December 31, 2020: $ — $ — $ — Charged to expense - employee termination benefits 12.9 62.7 75.6 Cash payments (0.1) (1.9) (2.0) Foreign currency translation gains (0.4) (2.0) (2.4) Balances as of March 31, 2021: $ 12.4 $ 58.8 $ 71.2

13. Leases (Notes)

13. Leases (Notes)	3 Months Ended
	Mar. 31, 2021
13. Leases [Abstract]
Leases of Lessee Disclosure [Text Block]	13. LEASES: FINANCE AND OPERATING WHERE WE ACT AS LESSEE For operating leases where we act as lessor in reagent rental agreements, see Note 1. We have operating leases and to a lesser extent finance leases, for buildings, vehicles and equipment. For operating leases, we have elected not to separate lease and non-lease components for buildings, vehicles and equipment. Our leases have remaining lease terms of 1 year to 18 years, which includes our determination to exercise renewal options. We determine if an arrangement is a lease at inception. Right-of-use (ROU) assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. Operating lease ROU assets also include any lease payments made and excludes lease incentives. Our lease terms may include options to extend or terminate the lease. For purposes of determining the lease term used in the measurement of operating lease ROU assets and operating lease liabilities, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if we are reasonably certain to exercise that option, the periods covered by an option to terminate the lease if we are reasonably certain not to exercise that option, and the periods covered by the option to extend (or to not terminate) the lease in which exercise of the option is controlled by the lessor. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The components of lease expense were as follows (in millions): Three Months Ended March 31, 2021 2020 Operating lease cost $ 11.7 $ 12.6 Finance lease cost: Amortization of right-of-use assets $ 0.1 $ 0.1 Interest on lease liabilities 0.2 0.2 Total finance lease cost $ 0.3 $ 0.3 Sublease income $ 0.7 $ 0.7 The sublease is for a building with a term that ends in 2025, with no options to extend or renew. Operating lease cost includes original reduction in the carrying amount of ROU assets, the impact of remeasurements, modifications, impairments and abandonments. Our short-term leases are expensed as incurred, reflecting leases with a lease term of one year or less, and are not significant for both the three months ended March 31, 2021 and 2020. Operating lease variable cost is primarily comprised of reimbursed actual common area maintenance, property taxes and insurance, which are immaterial for both the three months ended March 31, 2021 and 2020. Supplemental cash flow information related to leases was as follows (in millions): Three Months Ended March 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 11.8 $ 11.4 Operating cash flows from finance leases $ 0.1 $ 0.2 Financing cash flows from finance leases $ 0.2 $ 0.1 Right-of-use assets obtained in exchange for new lease obligations: Operating leases $ 4.2 $ 10.8 Finance leases $ — $ — Supplemental balance sheet information related to leases was as follows (in millions): March 31, 2021 December 31, 2020 Operating Leases Operating lease right-of-use assets $ 196.2 $ 202.1 Current operating lease liabilities $ 39.3 $ 36.5 Operating lease liabilities 168.3 175.1 Total operating lease liabilities $ 207.6 $ 211.6 Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities (in millions): March 31, 2021 December 31, 2020 Finance Leases Property, plant and equipment, gross $ 12.2 $ 12.2 Less: accumulated depreciation and amortization (5.1) (5.0) Property, plant and equipment, net $ 7.1 $ 7.2 Current maturities of long-term debt and notes payable $ 0.5 $ 0.5 Long-term debt, net of current maturities 10.9 11.0 Total finance lease liabilities $ 11.4 $ 11.5 March 31, 2021 December 31, 2020 Weighted Average Remaining Lease Term Operating leases - in years 8 8 Finance leases - in years 16 16 Weighted Average Discount Rate Operating leases 3.9 % 3.9 % Finance leases 6.2 % 6.2 % Maturities of lease liabilities were as follows (in millions): Year Ending December 31, Operating Leases Finance Leases 2021 (excluding the three months ended March 31, 2021) $ 35.3 $ 1.0 2022 38.6 1.3 2023 32.4 1.2 2024 26.4 1.1 2025 23.1 1.1 Thereafter 90.6 14.0 Total lease payments 246.4 19.7 Less imputed interest (38.8) (8.3) Total $ 207.6 $ 11.4 The value of our operating lease portfolio is principally for facilities with longer durations than the lesser value vehicles, and other equipment with shorter terms and higher-turn over.

1. Basis of Presentation and _2

1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Policies)	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Allowance for Doubtful Accounts We record trade accounts receivable at the net invoice value and such receivables are non-interest bearing. We consider receivables past due based on the contractual payment terms. We review our exposure to accounts receivable and reserve for amounts if collectability is no longer reasonably assured based on an assessment of various factors including historical loss rates and expectations of forward-looking loss estimates. Any adjustments made to our historical loss experience reflect current differences in asset-specific risk characteristics, including, for example, accounts receivable by customer type (public or government entity versus private entity) and by geographic location of customer. Changes in our allowance for doubtful accounts were as follows (in millions): Three Months Ended March 31, 2021 2020 Balance at beginning of period $ 19.8 $ 20.2 Provision (recovery) for expected credit losses (0.6) (0.8) Write-offs charged against the allowance (0.6) (0.5) Balance at end of period $ 18.6 $ 18.9
Standard Product Warranty, Policy [Policy Text Block]	We warrant certain equipment against defects in design, materials and workmanship, generally for a period of one year. We estimate the cost of warranties at the time the related revenue is recognized based on historical experience, specific warranty terms and customer feedback. These costs are recorded within Cost of goods sold in our condensed consolidated statements of income. Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the three month period ended March 31, 2021 and 2020 were as follows (in millions): Three Months Ended March 31, 2021 2020 Balance at beginning of period $ 9.8 $ 9.0 Provision for warranty 2.7 1.9 Actual warranty costs (2.6) (2.7) Balance at end of period $ 9.9 $ 8.2
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Adopted In March 2020, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2020-04, "Facilitation of the Effects of Reference Rate Reform on Financial Reporting (Topic 848)" The ASU provides optional expedients and exceptions for applying GAAP to transactions affected by reference rate (e.g., LIBOR) reform if certain criteria are met, for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The ASU is effective as of March 12, 2020 through December 31, 2022. We will evaluate transactions or contract modifications occurring as a result of reference rate reform and determine whether to apply the optional guidance on an ongoing basis. The ASU is currently not expected to have a material impact on our condensed consolidated financial statements. In January 2020, the FASB issued ASU 2020-01, "Clarifying the Interactions between Topic 321 Investments—Equity Securities, Topic 323 Investments—Equity Method and Joint Ventures, and Topic 815 Derivatives and Hedging." ASU 2020-01 clarifies that a company should consider observable transactions that require a company to either apply or discontinue the equity method of accounting under Topic 323 for the purposes of applying the measurement alternative in accordance with Topic 321 immediately before applying or upon discontinuing the equity method. ASU 2020-01 also clarifies that, when determining the accounting for certain forward contracts and purchased options a company should not consider, whether upon settlement or exercise, if the underlying securities would be accounted for under the equity method or fair value option. The ASU is currently not expected to have a material impact on our condensed consolidated financial statements. In December 2019, the FASB issued ASU 2019-12, "Simplifying the Accounting for Income Taxes," which eliminates certain exceptions within ASC 740, Income Taxes, and clarifies other aspects of the current guidance to promote consistency among reporting entities. ASU 2019-12 was effective for fiscal years beginning after December 15, 2020, with any adjustments reflected as of January 1, 2021. The adoption of ASU 2019-12 did not have a material impact on the condensed consolidated financial statements.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition We recognize revenue from operations through the sale of products, services, license of intellectual property and rental of instruments. Revenue from contracts with customers is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We enter into contracts that can include various combinations of products and services, which are generally accounted for as distinct performance obligations. Revenue is recognized net of any taxes collected from customers (sales tax, value added tax, etc.), which are subsequently remitted to government authorities. Our contracts from customers often include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require significant judgment, and may or may not impact the timing of revenue recognition. Revenue associated with equipment that requires factory installation is not recognized until installation is complete and customer acceptance, if required, has occurred. Certain equipment requires installation due to the fact that the instruments are being operated in a clinical/laboratory environment, and the installation services could result in modification of the equipment in order to ensure that the instruments are working according to customer specifications, which are subject to validation tests upon completion of the installation. In these arrangements, which require factory installation, the delivery of the equipment and the installation are separate performance obligations. We recognize the transaction price allocated to the equipment only upon customer acceptance, as the transfer of control in relation to the equipment has occurred at that point as the customer has the ability to direct the use of and obtain substantially all of the remaining benefits from the asset. The transaction price allocated to the installation services is also recognized upon customer acceptance because without the completion of the installation services and related customer acceptance the customer cannot receive any of the benefits of the service. At the time revenue is recognized, a provision is recorded for estimated product returns as this right is considered variable consideration. Accordingly, when product revenues are recognized, the transaction price is reduced by the estimated amount of product returns. Service revenues on extended warranty contracts are recognized ratably over the life of the service agreement as a stand-ready performance obligation. For arrangements that include a combination of products and services, the transaction price is allocated to each performance obligation based on stand-alone selling prices. The method used to determine the stand-alone selling prices for product and service revenues is based on the observable prices when the product or services have been sold separately. The primary purpose of our invoicing terms is to provide customers with simple and predictable methods of purchasing our products and services, not to either provide or receive financing to or from our customers. We record contract liabilities when cash payments are received or due in advance of our performance. We do not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Our payment terms vary by the type and location of our customer, and the products and services offered. The term between invoicing and when payment is due is not significant. Reagent Rental Agreements Reagent rental agreements are a diagnostic industry sales method that provides use of an instrument and consumables (reagents) to a customer on a per test basis. These agreements may also include maintenance of the instruments placed at customer locations as well as initial training. We initially determine if a reagent rental arrangement contains a lease at contract commencement. Where we have determined that such an arrangement contains a lease, we next must ascertain its lease classification for purposes of applying appropriate accounting treatment as an operating, sales-type or direct financing lease. For purposes of determining the lease term used in performing the lease classification test, we include the noncancellable period of the lease together with those periods covered by the option to extend the lease if the customer is reasonably certain to exercise that option, the periods covered by an option to terminate the lease if the customer is reasonably certain not to exercise that option, and the periods covered by the option to extend (or not to terminate) the lease in which exercise of the option is controlled by the Company. While most of our reagent rental arrangements contain either the option for a lessee to extend and/or cancel, the period in which the contract is enforceable is a very short period and therefore the lease term has been limited to the noncancellable period. Generally these arrangements do not contain an option for the lessee to purchase the underlying asset. We concluded that the use of the instrument (referred to as “lease elements”) is not within the guidance of ASC 606 but rather ASC 842. Accordingly, we first allocate the transaction price between the lease elements and the non-lease elements based on relative standalone selling prices. The determination of the transaction price requires judgment and consideration of any fixed/minimum payments as well as estimates of variable consideration. After allocation, the amount of variable payments allocated to lease components will be recognized as income under ASC 842, while the amount of variable payments allocated to non-lease components will be recognized as income in accordance with ASC 606. Maintenance services, along with the reagents, are allocated to the non-lease elements and are recognized as income. Generally, the terms of the arrangements result in the transfer of control for reagents upon either (i) when the consumables are delivered or (ii) when the consumables are consumed by the customer. Our reagent rental arrangements are predominantly comprised of variable lease payments that fluctuate depending on the volume of reagents purchased, as very few of such arrangements contain any fixed/minimum lease payments. Further, our reagent rental arrangements are predominantly classified as operating leases, and any sales-type leases represent in aggregate an immaterial amount of lease income. Our reported lease income is primarily variable in nature and is recognized upon delivery or as the reagents are consumed by the customer. Revenue allocated to the lease elements of these reagent rental arrangements represented approximately 2% and 3% of total revenue for the three months ended March 31, 2021 and March 31, 2020, respectively, and are included as part of Net sales in our condensed consolidated statements of income. Contract costs: As a practical expedient, we expense as incurred costs to obtain contracts as the amortization period would have been one year or less. These costs include our internal sales force and certain partner sales incentive programs and are recorded within Selling, general and administrative expense in our condensed consolidated statements of income. Disaggregation of Revenue: The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions): Three Months Ended March 31, 2021 2020 Europe $ 247.7 $ 195.7 Asia 168.9 111.4 United States 271.4 229.5 Other (primarily Canada and Latin America) 38.8 35.0 Total net sales $ 726.8 $ 571.6 The disaggregation of our revenue by geographic region is based primarily on the location of the use of the product or service, and by industry segment sources. The disaggregation of our revenue by industry segment sources are presented in our Segment Information footnote (see Note 10). Deferred revenues primarily represents unrecognized fees billed or collected for extended service arrangements. The deferred revenue balance at March 31, 2021 and December 31, 2020 was $66.2 million and $60.0 million, respectively. The short-term deferred revenue balance at March 31, 2021 and December 31, 2020 was $48.0 million and $42.5 million, respectively.

1. Basis of Presentation and _3

1. Basis of Presentation and Use of Estimates Basis of Presentation and Use of Estimates (Tables)	3 Months Ended
	Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Revenue from External Customers by Geographic Areas [Table Text Block]	The following table presents our revenues disaggregated by geographic region based primarily on the location of the use of the product or service (in millions): Three Months Ended March 31, 2021 2020 Europe $ 247.7 $ 195.7 Asia 168.9 111.4 United States 271.4 229.5 Other (primarily Canada and Latin America) 38.8 35.0 Total net sales $ 726.8 $ 571.6
Schedule of Product Warranty Liability [Table Text Block]	Warranty liabilities are included in Other current liabilities and Other long-term liabilities in the condensed consolidated balance sheets. Change in our warranty liability for the three month period ended March 31, 2021 and 2020 were as follows (in millions): Three Months Ended March 31, 2021 2020 Balance at beginning of period $ 9.8 $ 9.0 Provision for warranty 2.7 1.9 Actual warranty costs (2.6) (2.7) Balance at end of period $ 9.9 $ 8.2
Accounts Receivable, Allowance for Credit Loss [Table Text Block]	Changes in our allowance for doubtful accounts were as follows (in millions): Three Months Ended March 31, 2021 2020 Balance at beginning of period $ 19.8 $ 20.2 Provision (recovery) for expected credit losses (0.6) (0.8) Write-offs charged against the allowance (0.6) (0.5) Balance at end of period $ 18.6 $ 18.9

2. Fair Value Measurements (Tab

2. Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Fair Value Disclosures [Abstract]
Debt Securities, Available-for-sale [Table Text Block]	Available-for-sale investments consist of the following (in millions): March 31, 2021 Amortized Unrealized Unrealized Allowances for Credit Losses Fair Short-term investments: Corporate debt securities $ 160.3 $ 1.9 $ — $ — $ 162.2 Municipal obligations 14.0 0.1 — — 14.1 Asset-backed securities 27.7 0.3 — — 28.0 U.S. government sponsored agencies 70.6 1.3 (0.1) — 71.8 Foreign government obligations 4.0 — — — 4.0 Other foreign obligations 2.1 — — — 2.1 278.7 3.6 (0.1) — 282.2 Long-term investments: Asset-backed securities 0.1 — — — 0.1 0.1 — — — 0.1 Total $ 278.8 $ 3.6 $ (0.1) $ — $ 282.3	Available-for-sale investments consist of the following (in millions): December 31, 2020 Amortized Unrealized Unrealized Allowances for Credit Losses Estimated Short-term investments: Corporate debt securities $ 130.5 $ 2.7 $ — — $ 133.2 Municipal obligations 15.0 0.2 — — 15.2 Asset-backed securities 35.8 0.3 — — 36.1 U.S. government sponsored agencies 74.7 2.2 — — 76.9 Foreign government obligations 4.0 — — — 4.0 Other foreign obligations 2.1 — — — 2.1 262.1 5.4 — — 267.5 Long-term investments: Asset-backed securities 0.1 — — — 0.1 0.1 — — — 0.1 Total $ 262.2 $ 5.4 $ — $ — $ 267.6
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
Summary of fair value of gross unrealized losses for investments with unrealized losses	The following is a summary of investments with gross unrealized losses and the associated fair value (in millions): March 31, 2021 Less than 12 months Greater than 12 months Total Description of securities: Fair Value Unrealized Losses Fair Value Unrealized Losses Fair Value Unrealized Losses U.S. government sponsored agencies 7.4 0.1 — — 7.4 0.1 Total $ 7.4 $ 0.1 $ — $ — $ 7.4 $ 0.1
Discussion of current derivative risk management	The following is a summary of our forward foreign exchange contracts (in millions): March 31, 2021 Contracts maturing in April through June 2021 to sell foreign currency: Notional value $ 284.0 Unrealized loss $ 0.4 Contracts maturing in April through June 2021 to purchase foreign currency: Notional value $ 252.3 Unrealized gain or loss $ —
Summary of amortized cost and estimated fair value of debt securities by contractual maturity date	The following is a summary of the amortized cost and estimated fair value of our debt securities at March 31, 2021 by contractual maturity date (in millions): Amortized Estimated Fair Mature in less than one year $ 173.6 $ 174.1 Mature in one to five years 66.2 67.9 Mature in more than five years 39.0 40.3 Total $ 278.8 $ 282.3
Fair Value Measurements, Recurring and Nonrecurring	Financial assets and liabilities carried at fair value and measured on a recurring basis as of March 31, 2021 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 29.3 $ — $ 29.3 U.S. government sponsored agencies — 2.6 — 2.6 Time deposits 8.7 10.0 — 18.7 Money market funds 61.3 — — 61.3 Total cash equivalents (a) 70.0 41.9 — 111.9 Restricted investments (b) 6.8 — — 6.8 Equity securities (c) 10,524.3 — — 10,524.3 Available-for-sale investments: Corporate debt securities — 162.2 — 162.2 U.S. government sponsored agencies — 71.8 — 71.8 Foreign government obligations — 4.0 — 4.0 Other foreign obligations — 2.1 — 2.1 Municipal obligations — 14.1 — 14.1 Asset-backed securities — 28.1 — 28.1 Total available-for-sale investments (d) — 282.3 — 282.3 Forward foreign exchange contracts (e) — 0.6 — 0.6 Total financial assets carried at fair value $ 10,601.1 $ 324.8 $ — $ 10,925.9 Financial liabilities carried at fair value: Forward foreign exchange contracts (f) $ — $ 1.1 $ — $ 1.1 Contingent consideration (g) — — 0.7 0.7 Total financial liabilities carried at fair value $ — $ 1.1 $ 0.7 $ 1.8 Financial assets and liabilities carried at fair value and measured on a recurring basis as of December 31, 2020 are classified in the hierarchy as follows (in millions): Level 1 Level 2 Level 3 Total Financial assets carried at fair value: Cash equivalents: Commercial paper $ — $ 41.7 $ — $ 41.7 Time deposits 17.6 10.0 — 27.6 Asset-backed securities — 0.9 — 0.9 U.S. government sponsored agencies — 2.5 — 2.5 Money market funds 60.1 — — 60.1 Total cash equivalents (a) 77.7 55.1 — 132.8 Restricted investments (b) 6.7 — — 6.7 Equity securities (c) 9,582.4 — — 9,582.4 Available-for-sale investments: Corporate debt securities — 133.2 — 133.2 U.S. government sponsored agencies — 76.9 — 76.9 Foreign government obligations — 4.0 — 4.0 Other foreign obligations — 2.1 — 2.1 Municipal obligations — 15.2 — 15.2 Asset-backed securities — 36.2 — 36.2 Total available-for-sale investments (d) — 267.6 — 267.6 Forward foreign exchange contracts (e) — 1.0 — 1.0 Total financial assets carried at fair value $ 9,666.8 $ 323.7 $ — $ 9,990.5 Financial liabilities carried at fair value: Forward foreign exchange contracts (f) $ — $ 1.0 $ — $ 1.0 Contingent consideration (g) — — 0.7 0.7 Total financial liabilities carried at fair value $ — $ 1.0 $ 0.7 $ 1.7 (a) Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets. (b) Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions): March 31, 2021 December 31, 2020 Restricted investments $ 5.6 $ 5.6 Other investments 1.2 1.1 Total $ 6.8 $ 6.7 (c) Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions): March 31, 2021 December 31, 2020 Short-term investments $ 64.2 $ 61.4 Other investments 10,460.1 9,521.0 Total $ 10,524.3 $ 9,582.4 The change in fair market value on our equity securities for the three months ended March 31, 2021 was a $1,179.4 million gain, which was primarily due to our investment in Sartorius AG and is recorded in our condensed consolidated statements of income. As of March 31, 2021, we own 12,987,900 ordinary voting shares and 9,588,908 preferenc e shares of Sartorius AG (Sartorius), of Goettingen, Germany, a process technology supplier to the biotechnology, pharmaceutical, chemical and food and beverage industries. We own approximately 37% of the ordinary outstanding voting shares (excluding treasury shares) and 28% of the preference shares of Sartorius as of March 31, 2021. (d) Available-for-sale investments are included in the following accounts in the condensed consolidated balance sheets (in millions): March 31, 2021 December 31, 2020 Short-term investments $ 282.2 $ 267.5 Other investments 0.1 0.1 Total $ 282.3 $ 267.6 (e) Forward foreign exchange contracts in an asset position are included in other current assets in the condensed consolidated balance sheets. (f) Forward foreign exchange contracts in a liability position are included in other current liabilities in the condensed consolidated balance sheets. (g) Contingent consideration liability is included in the following accounts in the condensed consolidated balance sheets (in millions): March 31, 2021 December 31, 2020 Other current liabilities $ 0.6 $ 0.6 Other long-term liabilities 0.1 0.1 Total $ 0.7 $ 0.7

3. Intangible Assets, Goodwil_2

3. Intangible Assets, Goodwill and Other (Tables)	3 Months Ended
	Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Changes to goodwill by segment	Changes to goodwill by segment were as follows (in millions): Life Clinical Total Balances as of March 31, 2021 and December 31, 2020: Goodwill 277.9 349.2 627.1 Accumulated impairment losses (41.8) (293.4) (335.2) Goodwill, net $ 236.1 $ 55.8 $ 291.9
Schedule of identifiable purchased intangible assets with definite lives	Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions): March 31, 2021 Weighted-Average Remaining Amortization Period (years) Purchase Accumulated Net Customer relationships/lists 5.47 $ 112.4 $ (85.6) $ 26.8 Know how 4.50 192.7 (172.6) 20.1 Developed product technology 13.83 217.1 (108.6) 108.5 Licenses 7.51 65.2 (38.0) 27.2 Tradenames 7.71 6.4 (4.2) 2.2 Covenants not to compete 3.66 4.6 (2.2) 2.4 Other — 0.1 (0.1) — Total definite-lived intangible assets 598.5 (411.3) 187.2 In-process research and development 4.6 — 4.6 Total purchased intangible assets $ 603.1 $ (411.3) $ 191.8 December 31, 2020 Weighted-Average Remaining Amortization Period (years) Purchase Accumulated Net Customer relationships/lists 5.51 $ 116.6 $ (87.2) $ 29.4 Know how 4.75 196.6 (175.4) 21.2 Developed product technology 14.00 218.1 (107.1) 111.0 Licenses 7.73 65.6 (37.4) 28.2 Tradenames 7.82 6.6 (4.2) 2.4 Covenants not to compete 3.87 4.5 (2.0) 2.5 Other — 0.1 (0.1) — Total definite-lived intangible assets 608.1 (413.4) 194.7 In-process research and development 4.8 — 4.8 Total purchased intangible assets $ 612.9 $ (413.4) $ 199.5
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	Amortization expense related to purchased intangible assets is as follows (in millions): Three Months Ended March 31, 2021 2020 Amortization expense $ 7.2 $ 5.9

4. Supplemental Cash Flow Infor

4. Supplemental Cash Flow Information Cash Flow, Supplemental Disclosure - (Tables)	3 Months Ended
	Mar. 31, 2021
Supplemental Cash Flow Elements [Abstract]
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	The reconciliation of net income to net cash provided by operating activities is as follows (in millions): Three Months Ended March 31, 2021 March 31, 2020 Net income $ 977.4 $ 685.9 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 32.7 33.6 Reduction in the carrying amount of right-of-use assets 9.8 9.6 Share-based compensation 11.7 9.7 Gains on dispositions of securities (0.1) (0.4) Other-than-temporary impairment losses on investment 0.8 — Changes in fair market value of equity securities (1,179.4) (827.7) Losses on dispositions of fixed assets 0.3 0.1 Changes in fair value of contingent consideration — (0.1) Payments for operating lease liabilities (9.9) (9.3) Decrease in accounts receivable 1.3 2.2 Decrease (increase) in inventories 5.8 (13.7) Increase in other current assets (37.5) (9.5) Decrease in accounts payable and other current liabilities (44.5) (25.6) Increase in income taxes payable 27.3 20.9 Increase in deferred income taxes 274.8 171.8 Increase in other long term liabilities 43.8 15.7 Other (0.7) (0.4) Net cash provided by operating activities $ 113.6 $ 62.8 Non-cash investing activities: Purchased property, plant and equipment $ 4.7 $ 6.0 Purchased marketable securities and investments $ — $ 2.7

5. Long-Term Debt (Tables)

5. Long-Term Debt (Tables)	3 Months Ended
	Mar. 31, 2021
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments [Table Text Block]	The principal components of long-term debt are as follows (in millions): March 31, December 31, Finance leases and other debt $ 12.6 $ 14.1 Less current maturities (1.7) (1.8) Long-term debt $ 10.9 $ 12.3

6. Accumulated Other Comprehe_2

6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2021
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Accumulated other comprehensive income included in our condensed consolidated balance sheets consists of the following components (in millions): Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains on available-for-sale investments Total accumulated other comprehensive income (loss) Balances as of January 1, 2021: $ 298.6 $ (26.0) $ 9.8 $ 282.4 Other comprehensive (loss) income, before reclassifications (214.7) 1.7 (1.9) (214.9) Amounts reclassified from Accumulated other comprehensive income — 0.5 (0.1) 0.4 Income tax effects 0.4 (0.3) 0.4 0.5 Other comprehensive (loss) income, net of income taxes (214.3) 1.9 (1.6) (214.0) Balances as of March 31, 2021: $ 84.3 $ (24.1) $ 8.2 $ 68.4 Foreign currency translation adjustments Foreign other post-employment benefits adjustments Net unrealized holding gains on available-for-sale investments Total accumulated other comprehensive income (loss) Balances as of January 1, 2020: $ (72.4) $ (22.2) $ 7.2 $ (87.4) Other comprehensive (loss) income, before reclassifications (62.9) 0.2 — (62.7) Amounts reclassified from Accumulated other comprehensive income — 0.3 (0.4) (0.1) Income tax effects 0.9 0.2 0.1 1.2 Other comprehensive (loss) income, net of income taxes (62.0) 0.7 (0.3) (61.6) Balances as of March 31, 2020: $ (134.4) $ (21.5) $ 6.9 $ (149.0)

7. Earnings Per Share (Tables)

7. Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2021
Earnings Per Share [Abstract]
Schedule of weighted-average common shares outstanding used to calculate basic and diluted earnings per shares and the anti-dilutive shares	The weighted average number of common shares outstanding used to calculate basic and diluted earnings per share, and the anti-dilutive shares that are excluded from the diluted earnings per share calculation are as follows (in thousands): Three Months Ended March 31, 2021 2020 Basic weighted average shares outstanding 29,823 29,865 Effect of potentially dilutive stock options and restricted stock awards 363 331 Diluted weighted average common shares 30,186 30,196 Anti-dilutive shares 23 62

8. Other Income and Expenses (T

8. Other Income and Expenses (Tables)	3 Months Ended
	Mar. 31, 2021
Other Income and Expenses [Abstract]
Schedule of other income (expense), net	Other (income) expense, net includes the following components (in millions): Three Months Ended March 31, 2021 2020 Interest and investment income $ (18.3) $ (2.8) Net realized gains on investments (0.1) (0.4) Other-than-temporary impairment loss on investment 0.8 — Other expense (income) 0.2 (0.1) Other (income), net $ (17.4) $ (3.3)

10. Segment Information Segme_2

10. Segment Information Segment Reporting (Tables)	3 Months Ended
	Mar. 31, 2021
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Information regarding operating segments for the three months ended March 31, 2021 and 2020 is as follows (in millions): Life Clinical Other Segment net sales 2021 $ 366.5 $ 358.5 $ 1.8 2020 $ 227.2 $ 340.3 $ 4.1 Segment net profit (loss) 2021 $ 102.3 $ (1.9) $ 0.1 2020 $ 23.7 $ 43.8 $ 1.1
Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]	The following reconciles total segment profit to consolidated income before income taxes (in millions): Three Months Ended March 31, 2021 2020 Total segment profit $ 100.5 $ 68.6 Foreign currency exchange losses, net (0.1) (0.9) Change in fair market value of equity securities 1,179.4 827.7 Other income, net 17.4 3.3 Consolidated income before income taxes $ 1,297.2 $ 898.7

12. Restructuring Costs (Tables

12. Restructuring Costs (Tables)	3 Months Ended
	Mar. 31, 2021
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs [Table Text Block]	The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions): Life Science Clinical Diagnostics Total Balances as of December 31, 2020: $ — $ — $ — Charged to expense - employee termination benefits 12.9 62.7 75.6 Cash payments (0.1) (1.9) (2.0) Foreign currency translation gains (0.4) (2.0) (2.4) Balances as of March 31, 2021: $ 12.4 $ 58.8 $ 71.2

13. Leases (Tables)

13. Leases (Tables)	3 Months Ended
	Mar. 31, 2021
13. Leases [Abstract]
Lease, Cost [Table Text Block]	The components of lease expense were as follows (in millions): Three Months Ended March 31, 2021 2020 Operating lease cost $ 11.7 $ 12.6 Finance lease cost: Amortization of right-of-use assets $ 0.1 $ 0.1 Interest on lease liabilities 0.2 0.2 Total finance lease cost $ 0.3 $ 0.3 Sublease income $ 0.7 $ 0.7 The sublease is for a building with a term that ends in 2025, with no options to extend or renew.
Lessee Supplemental Cash Flow Information [Table Text Block]	Supplemental cash flow information related to leases was as follows (in millions): Three Months Ended March 31, 2021 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 11.8 $ 11.4 Operating cash flows from finance leases $ 0.1 $ 0.2 Financing cash flows from finance leases $ 0.2 $ 0.1 Right-of-use assets obtained in exchange for new lease obligations: Operating leases $ 4.2 $ 10.8 Finance leases $ — $ —
Maturities Of Lease Liabilities For Operating and Finance Leases [Table Text Block]	Maturities of lease liabilities were as follows (in millions): Year Ending December 31, Operating Leases Finance Leases 2021 (excluding the three months ended March 31, 2021) $ 35.3 $ 1.0 2022 38.6 1.3 2023 32.4 1.2 2024 26.4 1.1 2025 23.1 1.1 Thereafter 90.6 14.0 Total lease payments 246.4 19.7 Less imputed interest (38.8) (8.3) Total $ 207.6 $ 11.4
Lessee Supplemental Balance Sheet Information [Table Text Block]	Supplemental balance sheet information related to leases was as follows (in millions): March 31, 2021 December 31, 2020 Operating Leases Operating lease right-of-use assets $ 196.2 $ 202.1 Current operating lease liabilities $ 39.3 $ 36.5 Operating lease liabilities 168.3 175.1 Total operating lease liabilities $ 207.6 $ 211.6 Finance leases are included in Property, plant and equipment, Current maturities of long-term debt, and Long-term debt, net of current maturities (in millions): March 31, 2021 December 31, 2020 Finance Leases Property, plant and equipment, gross $ 12.2 $ 12.2 Less: accumulated depreciation and amortization (5.1) (5.0) Property, plant and equipment, net $ 7.1 $ 7.2 Current maturities of long-term debt and notes payable $ 0.5 $ 0.5 Long-term debt, net of current maturities 10.9 11.0 Total finance lease liabilities $ 11.4 $ 11.5 March 31, 2021 December 31, 2020 Weighted Average Remaining Lease Term Operating leases - in years 8 8 Finance leases - in years 16 16 Weighted Average Discount Rate Operating leases 3.9 % 3.9 % Finance leases 6.2 % 6.2 %

1. Basis of Presentation and _4

1. Basis of Presentation and Use of Estimates Organization, Consolidation and Presentation of Financial Statements (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Net sales	$ 726,796	$ 571,644
Cost of goods sold	326,169	254,276
Deferred Revenue	66,200		$ 60,000
Retained earnings	10,245,426		9,268,012
Accumulated other comprehensive loss	68,434		282,456
Total stockholders' equity	$ 10,609,059	$ 6,293,079	9,879,940	$ 5,755,057
Revenue Allocation Percent To Lease Elements	2.00%	3.00%
Additional paid-in-capital	$ 445,101		429,376
Selling, general and administrative expense	225,853	$ 193,692
Research and Development Expense	73,912	49,303
Interest expense	398	5,690
Other Nonoperating Income (Expense)	17,407	3,273
Deferred Revenue, Current	48,000		$ 42,500
Europe [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Net sales	247,700	195,700
Asia Pacific [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Net sales	168,900	111,400
UNITED STATES
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Net sales	271,400	229,500
Americas [Member]
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Net sales	$ 38,800	$ 35,000

1. Basis of Presentation and _5

1. Basis of Presentation and Use of Estimates Warranty Rollforward (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Warranty accrual, beginning of period	$ 9.8	$ 9
Provision for warranty	2.7	1.9
Actual warranty costs	(2.6)	(2.7)
Warranty accrual, end of period	$ 9.9	$ 8.2

1. Basis of Presentation and _6

1. Basis of Presentation and Use of Estimates Accounts Receivables Allowance for Credit Loss (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounts Receivable, Allowance for Credit Loss	$ 18.6	$ 18.9	$ 19.8	$ 20.2
Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)	(0.6)	(0.8)
Allowance for Loan and Lease Losses, Write-offs	$ (0.6)	$ (0.5)

2. Fair Value Measurements Fair

2. Fair Value Measurements Fair Value Level Table (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2021		Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Unrealized Gain on Securities		$ 1,179.4
Debt Securities, Available-for-sale		282.3
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value	[1]	6.8		$ 6.7
Equity Securities	[2]	10,524.3		9,582.4
Debt Securities, Available-for-sale	[3]	282.3		267.6
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[4]	0.6		1
Assets, Fair Value Disclosure		10,925.9		9,990.5
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[5]	1.1		1
Business Combination, Contingent Consideration, Liability	[6]	0.7		0.7
Liabilities, Fair Value Disclosure		1.8		1.7
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value	[1]	6.8		6.7
Equity Securities	[2]	10,524.3		9,582.4
Debt Securities, Available-for-sale	[3]	0		0
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[4]	0		0
Assets, Fair Value Disclosure		10,601.1		9,666.8
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[5]	0		0
Business Combination, Contingent Consideration, Liability	[6]	0		0
Liabilities, Fair Value Disclosure		0		0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value	[1]	0		0
Equity Securities	[2]	0		0
Debt Securities, Available-for-sale		282.3		267.6	[3]
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[4]	0.6		1
Assets, Fair Value Disclosure		324.8		323.7
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[5]	1.1		1
Business Combination, Contingent Consideration, Liability	[6]	0		0
Liabilities, Fair Value Disclosure		1.1		1
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value	[1]	0		0
Equity Securities	[2]	0		0
Debt Securities, Available-for-sale	[3]	0		0
Forward Foreign Exchange Contracts, Asset, Fair Value Disclosure	[4]	0		0
Assets, Fair Value Disclosure		0		0
Forward Foreign Exchange Contracts, Liability, Fair Value Disclosure	[5]	0		0
Business Combination, Contingent Consideration, Liability	[6]	0.7		0.7
Liabilities, Fair Value Disclosure		0.7		0.7
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure		0		0
Asset-backed Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]			0.9
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]			0
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]			0.9
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]			0
Commercial Paper [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	29.3		41.7
Commercial Paper [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	0		0
Commercial Paper [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	29.3		41.7
Commercial Paper [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	0		0
Time Deposits [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	18.7		27.6
Time Deposits [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	8.7		17.6
Time Deposits [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	10		10
Time Deposits [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	0		0
Money Market Funds [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	61.3		60.1
Money Market Funds [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	61.3		60.1
Money Market Funds [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	0		0
Money Market Funds [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	0		0
Cash Equivalents [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	111.9		132.8
Cash Equivalents [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	70		77.7
Cash Equivalents [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	41.9		55.1
Cash Equivalents [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure	[7]	0		0
US Treasury Securities | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure		2.6		2.5
US Treasury Securities | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure		2.6		2.5
US Treasury Securities | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure		0		0
Foreign Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		2.1	[3]	2.1
Foreign Government Debt [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0	[3]	0
Foreign Government Debt [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		2.1	[3]	2.1
Foreign Government Debt [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		0	[3]	0
Municipal Obligations (Member) | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	14.1		15.2
Municipal Obligations (Member) | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	0		0
Municipal Obligations (Member) | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	14.1		15.2
Municipal Obligations (Member) | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	0		0
Foreign Government Obligations [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	4		4
Foreign Government Obligations [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	0		0
Foreign Government Obligations [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	4		4
Foreign Government Obligations [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	0		0
Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	162.2		133.2
Corporate Debt Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	0		0
Corporate Debt Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	162.2		133.2
Corporate Debt Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	0		0
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	71.8		76.9
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	0		0
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	71.8		76.9
US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	0		0
Asset-backed Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	28.1		36.2
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	0		0
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	28.1		36.2
Asset-backed Securities [Member] | Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale	[3]	0		0
Other Current Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[6]	0.6		0.6
Other Noncurrent Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[6]	0.1		0.1
Short-term Investments [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities	[2]	64.2		61.4
Debt Securities, Available-for-sale	[3]	282.2		267.5
Short-term Investments [Member] | Foreign Government Debt [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		2.1		2.1
Short-term Investments [Member] | Municipal Obligations (Member) | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		14.1		15.2
Short-term Investments [Member] | Foreign Government Obligations [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		4		4
Short-term Investments [Member] | Corporate Debt Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		162.2		133.2
Short-term Investments [Member] | US Government Sponsored Agencies [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		71.8		76.9
Short-term Investments [Member] | Asset-backed Securities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale		28		36.1
Other Investments [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		1.2		1.1
Equity Securities	[2]	10,460.1		9,521
Debt Securities, Available-for-sale	[3]	0.1		0.1
Restricted investment [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted Investments, at Fair Value		$ 5.6		$ 5.6
[1]	Restricted investments are included in the following accounts in the condensed consolidated balance sheets (in millions): March 31, 2021 December 31, 2020 Restricted investments $ 5.6 $ 5.6 Other investments 1.2 1.1 Total $ 6.8 $ 6.7
[2]	Equity securities are included in the following accounts in the condensed consolidated balance sheets (in millions): March 31, 2021 December 31, 2020 Short-term investments $ 64.2 $ 61.4 Other investments 10,460.1 9,521.0 Total $ 10,524.3 $ 9,582.4
[3]	Available-for-sale investments are included in the following accounts in the condensed consolidated balance sheets (in millions): March 31, 2021 December 31, 2020 Short-term investments $ 282.2 $ 267.5 Other investments 0.1 0.1 Total $ 282.3 $ 267.6
[4]	Forward foreign exchange contracts in an asset position are included in other current assets in the condensed consolidated balance sheets.
[5]	Forward foreign exchange contracts in a liability position are included in other current liabilities in the condensed consolidated balance sheets.
[6]	Contingent consideration liability is included in the following accounts in the condensed consolidated balance sheets (in millions): March 31, 2021 December 31, 2020 Other current liabilities $ 0.6 $ 0.6 Other long-term liabilities 0.1 0.1 Total $ 0.7 $ 0.7
[7]	Cash equivalents are included in Cash and cash equivalents in the condensed consolidated balance sheets.

2. Fair Value Measurements 3. C

2. Fair Value Measurements 3. Contingent Consideration (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2021	Dec. 31, 2020	Apr. 01, 2020
Distributor [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration milestone payments		$ (1.4)	$ (0.7)
Business Combination, Contingent Consideration, Liability		0.6
Celsee
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		60
Business Combination, Contingent Consideration, Liability		0.1		$ 0.1
Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[1]	0.7	0.7
Other Noncurrent Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[1]	0.1	0.1
Other Current Liabilities [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability	[1]	$ 0.6	$ 0.6
[1]	Contingent consideration liability is included in the following accounts in the condensed consolidated balance sheets (in millions): March 31, 2021 December 31, 2020 Other current liabilities $ 0.6 $ 0.6 Other long-term liabilities 0.1 0.1 Total $ 0.7 $ 0.7

2. Foreign Exchange Forward Con

2. Foreign Exchange Forward Contracts (Details) $ in Millions	3 Months Ended
	Mar. 31, 2021USD ($)
Forward foreign exchange contract to sell foreign currency [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	$ 284
Loss on Foreign Currency Derivative Instruments not Designated as Hedging Instruments	0.4
Forward foreign exchange contract to purchase foreign currency [Member]
Derivatives, Fair Value [Line Items]
Derivative, Notional Amount	252.3
Loss on Foreign Currency Derivative Instruments not Designated as Hedging Instruments	$ 0

2. Available-for-Sale Investmen

2. Available-for-Sale Investments (Details) - USD ($) $ in Millions		Mar. 31, 2021		Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		$ 278.8
Debt Securities, Available-for-sale		282.3
Fair Value, Recurring [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		278.8		$ 262.2
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		3.6		5.4
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(0.1)		0
Debt Securities, Available-for-sale, Allowance for Credit Loss		0		0
Debt Securities, Available-for-sale	[1]	282.3		267.6
Fair Value, Recurring [Member] | Corporate Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	162.2		133.2
Fair Value, Recurring [Member] | Municipal obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	14.1		15.2
Fair Value, Recurring [Member] | US Government Sponsored Agencies [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	71.8		76.9
Fair Value, Recurring [Member] | Foreign Government Obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	4		4
Fair Value, Recurring [Member] | Foreign Government Debt [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale		2.1	[1]	2.1
Fair Value, Recurring [Member] | Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	28.1		36.2
Fair Value, Recurring [Member] | Other Long-term Investments [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		0.1		0.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0		0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0		0
Debt Securities, Available-for-sale, Allowance for Credit Loss		0		0
Debt Securities, Available-for-sale		0.1		0.1
Fair Value, Recurring [Member] | Other Long-term Investments [Member] | Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		0.1		0.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0		0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0		0
Debt Securities, Available-for-sale, Allowance for Credit Loss		0		0
Debt Securities, Available-for-sale		0.1		0.1
Fair Value, Recurring [Member] | Short-term Investments [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		278.7		262.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		3.6		5.4
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(0.1)		0
Debt Securities, Available-for-sale, Allowance for Credit Loss		0		0
Debt Securities, Available-for-sale	[1]	282.2		267.5
Fair Value, Recurring [Member] | Short-term Investments [Member] | Corporate Debt Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		160.3		130.5
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		1.9		2.7
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0		0
Debt Securities, Available-for-sale, Allowance for Credit Loss		0		0
Debt Securities, Available-for-sale		162.2		133.2
Fair Value, Recurring [Member] | Short-term Investments [Member] | Municipal obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		14		15
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0.1		0.2
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0		0
Debt Securities, Available-for-sale, Allowance for Credit Loss		0		0
Debt Securities, Available-for-sale		14.1		15.2
Fair Value, Recurring [Member] | Short-term Investments [Member] | US Government Sponsored Agencies [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		70.6		74.7
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		1.3		2.2
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		(0.1)		0
Debt Securities, Available-for-sale, Allowance for Credit Loss		0		0
Debt Securities, Available-for-sale		71.8		76.9
Fair Value, Recurring [Member] | Short-term Investments [Member] | Foreign Government Obligations [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		4		4
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0		0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0		0
Debt Securities, Available-for-sale, Allowance for Credit Loss		0		0
Debt Securities, Available-for-sale		4		4
Fair Value, Recurring [Member] | Short-term Investments [Member] | Foreign Government Debt [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		2.1		2.1
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0		0
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0		0
Debt Securities, Available-for-sale, Allowance for Credit Loss		0		0
Debt Securities, Available-for-sale		2.1		2.1
Fair Value, Recurring [Member] | Short-term Investments [Member] | Asset-backed Securities [Member]
Debt Securities, Available-for-sale [Line Items]
Amortized Cost		27.7		35.8
Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax		0.3		0.3
Available-for-sale Securities, Accumulated Gross Unrealized Loss, before Tax		0		0
Debt Securities, Available-for-sale, Allowance for Credit Loss		0		0
Debt Securities, Available-for-sale		28		36.1
Fair Value, Recurring [Member] | Other Investments [Member]
Debt Securities, Available-for-sale [Line Items]
Debt Securities, Available-for-sale	[1]	$ 0.1		$ 0.1
[1]	Available-for-sale investments are included in the following accounts in the condensed consolidated balance sheets (in millions): March 31, 2021 December 31, 2020 Short-term investments $ 282.2 $ 267.5 Other investments 0.1 0.1 Total $ 282.3 $ 267.6

2. Amortized Cost and Fair Valu

2. Amortized Cost and Fair Value of Debt Securities (Details) $ in Millions	Mar. 31, 2021USD ($)
Fair Value Disclosures [Abstract]
Mature in less than one year	$ 173.6
Mature in one to five years	66.2
Mature in more than five years	39
Total Amortized Cost	278.8
Mature in less than one year	174.1
Mature in one to five years	67.9
Mature in more than five years	40.3
Estimated Fair Value	$ 282.3

2. Fair Value and Gross Unreali

2. Fair Value and Gross Unrealized Losses with Unrealized Losses (Details) $ in Millions	Mar. 31, 2021USD ($)
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	$ 0.1
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	0
Debt Securities, Available-for-sale, Unrealized Loss Position	7.4
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months	7.4
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer	0
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	0.1
US Government Sponsored Agencies [Member]
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	0.1
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	0
Debt Securities, Available-for-sale, Unrealized Loss Position	7.4
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months	7.4
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer	0
Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	0.1
Fair Value, Recurring [Member] | Debt Securities [Member]
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	$ 0.1

2. Fair Value Financial Instrum

2. Fair Value Financial Instruments (Details) - USD ($) $ in Millions	Mar. 31, 2021	Dec. 31, 2020
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Interest Receivable, Current	$ 1.4	$ 1.4
Equity Securities without Readily Determinable Fair Value, Amount	6.5	0.5
Equity Method Investments	$ 35.2	$ 38.4
Ordinary voting shares [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment ownership percentage	37.00%
Investment Owned, Balance, Shares	12,987,900
Preference shares [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Investment ownership percentage	28.00%
Investment Owned, Balance, Shares	9,588,908

3. Intangible Assets, Goodwil_3

3. Intangible Assets, Goodwill and Other (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Goodwill [Line Items]
Goodwill	$ 627,100	$ 627,100
Accumulated impairment loss	(335,200)	(335,200)
Goodwill, net	291,916	291,916
Clinical Diagnostics [Member]
Goodwill [Line Items]
Goodwill	349,200	349,200
Accumulated impairment loss	(293,400)	(293,400)
Goodwill, net	55,800	55,800
Life Science [Member]
Goodwill [Line Items]
Goodwill	277,900	277,900
Accumulated impairment loss	(41,800)	(41,800)
Goodwill, net	$ 236,100	$ 236,100

3. Intangible Assets, Goodwil_4

3. Intangible Assets, Goodwill and Other Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 598.5		$ 608.1
Accumulated Amortization	(411.3)		(413.4)
Net Carrying Amount	187.2		194.7
Amortization [Abstract]
Amortization expense	7.2	$ 5.9
Intangible Assets, Gross (Excluding Goodwill)	$ 603.1		$ 612.9
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	5 years 5 months 19 days		5 years 6 months 3 days
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 112.4		$ 116.6
Accumulated Amortization	(85.6)		(87.2)
Net Carrying Amount	$ 26.8		$ 29.4
Know How [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	4 years 6 months		4 years 9 months
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 192.7		$ 196.6
Accumulated Amortization	(172.6)		(175.4)
Net Carrying Amount	$ 20.1		$ 21.2
Developed Technology Rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	13 years 9 months 29 days		14 years
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 217.1		$ 218.1
Accumulated Amortization	(108.6)		(107.1)
Net Carrying Amount	$ 108.5		$ 111
Licensing Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	7 years 6 months 3 days		7 years 8 months 23 days
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 65.2		$ 65.6
Accumulated Amortization	(38)		(37.4)
Net Carrying Amount	$ 27.2		$ 28.2
Trade Names [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	7 years 8 months 15 days		7 years 9 months 25 days
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 6.4		$ 6.6
Accumulated Amortization	(4.2)		(4.2)
Net Carrying Amount	$ 2.2		$ 2.4
Noncompete Agreements [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period	3 years 7 months 28 days		3 years 10 months 13 days
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 4.6		$ 4.5
Accumulated Amortization	(2.2)		(2)
Net Carrying Amount	$ 2.4		$ 2.5
Other Intangible Assets [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Remaining Amortization Period
Finite-Lived Intangible Assets, Net [Abstract]
Purchase Price	$ 0.1		$ 0.1
Accumulated Amortization	(0.1)		(0.1)
Net Carrying Amount	0		0
In Process Research and Development [Member]
Amortization [Abstract]
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 4.6		$ 4.8

4. Supplemental Cash Flow Inf_2

4. Supplemental Cash Flow Information - (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Supplemental Cash Flow Elements [Abstract]
Net Income Attributable to Parent	$ 977,414	$ 685,912
Share-based Compensation	11,700	9,700
(Gain) Loss on Sale of Securities, Net	(100)	(400)
Other than temporary impairment losses on investments	800	0
Changes in fair market value of equity securities	(1,179,400)	(827,700)
Loss on Disposition of Property Plant Equipment	300	100
Changes in fair value of contingent consideration	0	(100)
Decrease in accounts receivable	1,300	2,200
Decrease (increase) in inventories	5,800	(13,700)
Increase in other current assets	(37,500)	(9,500)
Decrease in accounts payable and other current liabilities	(44,500)	(25,600)
Increase in income taxes payable	27,300	20,900
Increase in deferred income taxes	274,800	171,800
Increase in other long term liabilities	43,800	15,700
Reduction in the carrying amount of right-of-use assets	9,800	9,600
Depreciation and amortization	32,700	33,600
Other	(700)	(400)
Payments of operating lease liabilities	(9,900)	(9,300)
Net cash provided by operating activities	113,610	62,808
Noncash or Part Noncash Acquisition, Investments Acquired	0	2,700
Noncash or Part Noncash Acquisition, Fixed Assets Acquired	$ 4,700	$ 6,000

5. Long-Term Debt (Details)

5. Long-Term Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Other Long-term Debt, Current	$ 1,700	$ 1,800
Long-term debt, net of current maturities	10,901	12,258
Outstanding borrowings	0
Finance Lease Obligations [Member] | Finance Leases and Other Debt [Member]
Debt Instrument [Line Items]
Other Long-term Debt	12,600	$ 14,100
Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit maximum borrowing capacity	$ 200,000
Line of Credit Facility, Interest Rate at Period End	1.315%
Standby Letters of Credit [Member]
Debt Instrument [Line Items]
Line of credit maximum borrowing capacity	$ 200

6. Accumulated Other Comprehe_3

6. Accumulated Other Comprehensive Income 6. Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income	$ 282,456
Total other comprehensive income (loss) net of tax	(214,022)	$ (61,607)
Ending balance, Accumulated other comprehensive income	68,434
Other (income) expense, net	(17,407)	(3,273)
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income	298,600	(72,400)
Other Comprehensive Income (Loss), before Reclassifications, before Tax	(214,700)	(62,900)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	0	0
Other Comprehensive Income (Loss), Tax	400	900
Total other comprehensive income (loss) net of tax	(214,300)	(62,000)
Ending balance, Accumulated other comprehensive income	84,300	(134,400)
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income	(26,000)	(22,200)
Other Comprehensive Income (Loss), before Reclassifications, before Tax	1,700	200
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	500	300
Other Comprehensive Income (Loss), Tax	(300)	200
Total other comprehensive income (loss) net of tax	1,900	700
Ending balance, Accumulated other comprehensive income	(24,100)	(21,500)
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income	9,800	7,200
Other Comprehensive Income (Loss), before Reclassifications, before Tax	(1,900)	0
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	(100)	(400)
Other Comprehensive Income (Loss), Tax	400	100
Total other comprehensive income (loss) net of tax	(1,600)	(300)
Ending balance, Accumulated other comprehensive income	8,200	6,900
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance, Accumulated other comprehensive income	282,400	(87,400)
Other Comprehensive Income (Loss), before Reclassifications, before Tax	(214,900)	(62,700)
Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax	400	(100)
Other Comprehensive Income (Loss), Tax	500	1,200
Total other comprehensive income (loss) net of tax	(214,000)	(61,600)
Ending balance, Accumulated other comprehensive income	$ 68,400	$ (149,000)

7. Earnings Per Share (Details)

7. Earnings Per Share (Details) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Basic weighted average shares outstanding	29,823	29,865
Effect of potentially dilutive stock options and restricted stock awards	363	331
Diluted weighted average common shares	30,186	30,196
Anti-dilutive shares	23	62

8. Other Income and Expenses (D

8. Other Income and Expenses (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Interest and investment income	$ (18,300)	$ (2,800)
Net realized (gain) loss on investments	(100)	(400)
Other Nonoperating (Income)		(100)
Other Nonoperating Expense	200
Equity Method Investment, Other than Temporary Impairment	800	0
Other Nonoperating Income (Expense)	$ 17,407	$ 3,273

9. Income Taxes (Details)

9. Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Effective tax rate	24.70%	23.70%
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit	$ 16.7
Unrecognized Tax Benefits	57.5		$ 55.8
Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions	$ 1.7

Segment Reporting (Details)

Segment Reporting (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Segment Reporting Information [Line Items]
Net sales	$ 726,796	$ 571,644
Income before income taxes	1,297,203	898,699
Life Science [Member]
Segment Reporting Information [Line Items]
Net sales	366,500	227,200
Income before income taxes	102,300	23,700
Clinical Diagnostics [Member]
Segment Reporting Information [Line Items]
Net sales	358,500	340,300
Income before income taxes	(1,900)	43,800
Other Segments [Member]
Segment Reporting Information [Line Items]
Net sales	1,800	4,100
Income before income taxes	$ 100	$ 1,100

10. Segment Information Segme_3

10. Segment Information Segment Profit Reconciliations (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	$ 1,297,203	$ 898,699
Marketable Securities, Unrealized Gain (Loss)	1,179,403	827,671
Operating Segments [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	100,500	68,600
Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Marketable Securities, Unrealized Gain (Loss)	1,179,400	827,700
Foreign Currency Gain (Loss) [Member] | Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	(100)	(900)
Other Nonoperating Income (Expense) [Member] | Segment Reconciling Items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Income before income taxes	$ 17,400	$ 3,300

10. Segment Information Segme_4

10. Segment Information Segment Asset Reconciliation (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Segment Reporting, Asset Reconciling Item [Line Items]
Assets	$ 13,933,160	$ 12,972,618

12. Restructuring Costs (Detail

12. Restructuring Costs (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Restructuring Cost and Reserve [Line Items]
Cost of goods sold	$ 326,169	$ 254,276
European Reorganization
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	71,200		$ 0
Restructuring Charges	75,600
Payments for Restructuring	(2,000)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss	(2,400)
European Reorganization | Accounts Payable and Accrued Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	35,200
European Reorganization | Other Noncurrent Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	36,000
European Reorganization | Selling, General and Administrative Expenses [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	34,700
European Reorganization | Cost of Sales [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	23,900
European Reorganization | Research and Development Expense [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve, Accrual Adjustment	17,000
European Reorganization | Life Science [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	12,400		0
Restructuring Charges	12,900
Payments for Restructuring	(100)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss	(400)
European Reorganization | Clinical Diagnostics [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	58,800		$ 0
Restructuring Charges	62,700
Payments for Restructuring	(1,900)
Restructuring Reserve, Foreign Currency Translation (Gain) Loss	$ (2,000)

13. Leases (Details)

13. Leases (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Lessee, Lease, Description [Line Items]
Operating Lease, Cost	$ 11,700	$ 12,600
Finance Lease, Right-of-Use Asset, Amortization	100	100
Finance Lease, Interest Expense	200	200
Finance Lease Cost	300	300
Sublease Income	700	700
Operating Lease, Payments	11,800	11,400
Finance Lease, Interest Payment on Liability	100	200
Finance Lease, Principal Payments	200	100
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	4,200	10,800
Right-of-Use Asset Obtained in Exchange for Finance Lease Liability	0	$ 0
Operating lease right-of-use assets	196,224		$ 202,136
Current operating lease liabilities	39,235		36,507
Operating lease liabilities	168,326		175,128
Operating Lease, Liability	207,600		211,600
Finance Lease, Right-Of-Use Asset, before Accumulated Amortization	12,200		12,200
Finance Lease, Right-Of-Use Asset, Accumulated Amortization	5,100		5,000
Finance Lease, Right-Of-Use Asset, after Accumulated Amortization	7,100		7,200
Finance Lease, Liability, Current	500		500
Finance Lease, Liability, Noncurrent	10,900		11,000
Finance Lease, Liability	$ 11,400		$ 11,500
Operating Lease, Weighted Average Remaining Lease Term	8 years		8 years
Finance Lease, Weighted Average Remaining Lease Term	16 years		16 years
Operating Lease, Weighted Average Discount Rate, Percent	3.90%		3.90%
Finance Lease, Weighted Average Discount Rate, Percent	6.20%		6.20%
Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year	$ 35,300
Finance Lease, Liability, Payments, Remainder of Fiscal Year	1,000
Lessee, Operating Lease, Liability, to be Paid, Year One	38,600
Finance Lease, Liability, to be Paid, Year One	1,300
Lessee, Operating Lease, Liability, Payments, Due Year Two	32,400
Finance Lease, Liability, Payments, Due Year Two	1,200
Lessee, Operating Lease, Liability, Payments, Due Year Three	26,400
Finance Lease, Liability, Payments, Due Year Three	1,100
Lessee, Operating Lease, Liability, Payments, Due Year Four	23,100
Finance Lease, Liability, Payments, Due Year Four	1,100
Lessee, Operating Lease, Liability, Payments, Due after Year Five	90,600
Finance Lease, Liability, Payments, Due after Year Five	14,000
Lessee, Operating Lease, Liability, Payments, Due	246,400
Finance Lease, Liability, Payment, Due	19,700
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	(38,800)
Finance Lease, Liability, Undiscounted Excess Amount	(8,300)
Current liability
Lessee, Lease, Description [Line Items]
Current operating lease liabilities	$ 39,300		$ 36,500
Minimum [Member]
Lessee, Lease, Description [Line Items]
Lessee Operating And Finance Leases Remaining Lease Term	1 year
Maximum [Member]
Lessee, Lease, Description [Line Items]
Lessee Operating And Finance Leases Remaining Lease Term	18 years